Thursday 6-12-2014 Merck & Company (MRK) $MRK opened at 58.35 hitting the high price of 58.72 and a day low of 58.06 with a total volume of 9,563,877. MRK had a previous close of 58.81 and has been seeing an average volume of 7,958,185.
Overall Average: 80% Buy
Recent stock forum discussions about MRK http://investorshangout.com/search?q=MRK&...mp;yt0=Go!
As the Dow Declines, Why Are Pfizer and Merck Rising?
Dan Caplinger, The Motley Fool - Motley Fool - Thu Jun 12, 11:31AM CDT
The Dow Jones Industrials was down 50 points as of 12:30 p.m. EDT Thursday, extending the previous day's loss . With unrest in Iraq helping to boost energy prices , the prospects for consumers having to pay more at the pump and for businesses... (full story)
Watch for Shares of Merck (MRK) to Approach Support at $58.12
Comtex SmarTrend(R) - Thu Jun 12, 9:41AM CDT
Merck (NYSE:MRK) has opened bearishly below the pivot of $58.75 today and has reached the first level of support at $58.46. Investors may be interested in a cross of the next downside pivot targets of $58.12 and $57.49. (full story)
Will This Price Target Increase Help Merck (MRK) Stock Today?
at The Street - Thu Jun 12, 8:22AM CDT
Bank of America-Merrill Lynch raises its price target for Merck (MRK) to $65, saying the Indentix purchase should add to earnings. (full story)
Latin America Nutraceuticals Industry Outlook to 2017 - Mexico and Brazil to Lead Growth
M2 - Thu Jun 12, 8:19AM CDT
Research and Markets (http://www.researchandmarkets.com/research/9vxhxk/latin_america) has announced the addition of the "Latin America Nutraceuticals Industry Outlook to 2017 - Mexico and Brazil to Lead Growth" report to their offering. The industry research report on -Latin America Nutraceuticals Industry Outlook to 2017 - Mexico and Brazil to Lead Growth- gives a comprehensive analysis of the nutraceutical industry past, present and future outlook. The report discusses Mexico and Brazil markets with outlook to 2017. Statistics include functional food, functional beverages and dietary supplements market size and competitive analysis. Additionally the sub-segments of the industry, ongoing trends and developments, import and export scenario, government regulations and impact are provided in the research publication. Key Topics covered in the report - The market size of the Latin America, Mexico and Brazil nutraceuticals industry on the basis of revenues - Market segmentation of the Latin America Nutraceuticals industry on the basis of types of products and benefits derived - Market segmentation of the Latin America Dietary supplements market on the basis of geography and distribution channels - Market Share of major players in Latin America Dietary supplements market - Market segmentation of the Mexico and Brazil Nutraceuticals industry on the basis of types of products - Market segmentation of the Functional Food and Beverages on the basis of product form in Mexico and Brazil - Market size of the Functional Foods and Functional Beverages in Mexico and Brazil Key Topics Covered: 1. Latin America Nutraceuticals Industry Introduction 2. Latin America Nutraceuticals Industry Size, 2006-2012 3. Latin America Nutraceuticals Market Segmentation 4. Latin America Nutraceuticals Industry Future Outlook and Projections, 2013-2017 5. Mexico Nutraceuticals Industry Introduction 6. Brazil Nutraceuticals Industry Introduction 7. Appendix Companies Mentioned: - Boehringer Ingelheim GmbH - Amway - Bayer HealthCare LLC - Groupe Danone - Herbalife - Ind?stria de Alimentos Bomgosto - M Dias Branco SA Ind?stria e Com?r - Merck Sharp & Dohme Corp - Nestle SA - Omnilife Group - PepsiCo - Pfizer Nutrition For more information visit http://www.researchandmarkets.com/research/9v...in_america (full story)
2014 Report on the International Antibacterial Drugs (minoglycosides, B-Lactams, Tetracyclines, Sulfonamides, Quinolones/ Fluoroquinolones, Macrolides and Phenicols) Market - Forecast to 2019
PR Newswire Europe - Thu Jun 12, 7:15AM CDT
Research and Markets (http://www.researchandmarkets.com/research/l2jzql/antibacterial [http://www.researchandmarkets.com/research/l2jzql/antibacterial]) has announced the addition of the "Antibacterial Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019" [http://www.researchandmarkets.com/research/l2jzql/antibacterial] report to their offering. (full story)
Alnylam Announces United States Patent and Trademark Office (USPTO) Issues Patent Covering RNAi Therapeutics for the Treatment of Hepatitis B Virus (HBV) Infection
Business Wire - Thu Jun 12, 7:01AM CDT
Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), a leading RNAi therapeutics company, announced today that the United States Patent and Trademark Office (USPTO) has issued a new patent (U.S. patent no. 8,618,277, or "'277 patent"
in the company's McSwiggen patent estate. The McSwiggen patent estate broadly describes chemical modifications of RNAi therapeutics needed to achieve "drug-like" properties in siRNA, the molecules that mediate RNAi. Specifically, the '277 patent includes claims that the company believes are critical for the development of RNAi therapeutics for the treatment of hepatitis B virus (HBV) infection. This patent is held exclusively by Alnylam and is not licensed to any third parties. The McSwiggen patent estate comprises a core component of Alnylam's overall intellectual property (IP) estate for the advancement of RNAi therapeutics, and was recently obtained through the company's acquisition of Sirna Therapeutics from Merck. (full story)
Prophylactic Human Papillomavirus Vaccines Market Forecast to 2022
M2 - Thu Jun 12, 5:40AM CDT
RnRMarketResearch.com adds "PharmaPoint: Prophylactic Human Papillomavirus Vaccines - Global Drug Forecast and Market Analysis to 2022" report to its research database. (full story)
Renal Cell Carcinoma - Pipeline Review, H1 2014
M2 - Thu Jun 12, 3:49AM CDT
Research and Markets (http://www.researchandmarkets.com/research/5lwrwg/renal_cell) has announced the addition of the "Renal Cell Carcinoma - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Renal Cell Carcinoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Renal Cell Carcinoma and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Renal Cell Carcinoma - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Renal Cell Carcinoma and enlists all their major and minor projects Companies Mentioned: - Bristol-Myers Squibb - Boehringer Ingelheim - Kyowa Hakko Kirin - Amgen - Eli Lilly and Company - GlaxoSmithKline - Seattle Genetics - Genentech - Agenus - Merck & Co - Celltrion - Astellas Pharma - ImmunoGen - Ono - Pfizer - Taiho - Onyx - Bayer - Advaxis - Hemispherx - Celldex Therapeutics, Inc. - Active Biotech AB - Lorus Therapeutics Inc. - Lpath, Inc. - Bionomics Limited - Flamel Technologies S.A. - Mologen AG - Threshold Pharmaceuticals, Inc. - Colby Pharmaceutical Company - Wilex AG For more information visit http://www.researchandmarkets.com/research/5lwrwg/renal_cell (full story)
Complicated Intra-Abdominal Infections - Pipeline Review, H1 2014
M2 - Thu Jun 12, 3:03AM CDT
Research and Markets (http://www.researchandmarkets.com/research/qlldl7/complicated) has announced the addition of the "Complicated Intra-Abdominal Infections - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Complicated Intra-Abdominal Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Complicated Intra-Abdominal Infections and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Complicated Intra-Abdominal Infections - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Complicated Intra-Abdominal Infections and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects Companies Mentioned: - AstraZeneca PLC - Merck & Co., Inc. - Melinta Therapeutics, Inc - Cubist Pharmaceuticals, Inc. - MerLion Pharmaceuticals Pte Ltd - Atox Bio Inc. - Tetraphase Pharmaceuticals Inc. - Biota Pharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/ql...omplicated (full story)
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline Review, H1 2014
M2 - Thu Jun 12, 2:52AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7cwmg2/coronary_artery) has announced the addition of the "Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Coronary Artery Disease (CAD) (Ischemic Heart Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Coronary Artery Disease (CAD) (Ischemic Heart Disease) and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Coronary Artery Disease (CAD) (Ischemic Heart Disease) Companies Mentioned: - Bristol-Myers Squibb Company - AstraZeneca - MedImmune - Isis Pharmaceuticals - Gilead Sciences - Daiichi Sankyo Company - Merck & Co - CardioVascular BioTherapeutics - Bayer AG - AnGes MG - Pluristem Therapeutics - AngioDesign - ViroMed - Miltenyi Biotec - Multi Gene Vascular Systems - Lonestar Heart - Biscayne Pharmaceuticals For more information visit http://www.researchandmarkets.com/research/7c...ary_artery (full story)
B-Cell Non-Hodgkin Lymphoma - Pipeline Review, H1 2014
M2 - Thu Jun 12, 2:39AM CDT
Research and Markets (http://www.researchandmarkets.com/research/fvkt8j/bcell) has announced the addition of the "B-Cell Non-Hodgkin Lymphoma - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for B-Cell Non-Hodgkin Lymphoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for B-Cell Non-Hodgkin Lymphoma and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of B-Cell Non-Hodgkin Lymphoma - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for B-Cell Non-Hodgkin Lymphoma and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects Companies Mentioned: - Bristol-Myers Squibb Company - Johnson & Johnson - Boehringer Ingelheim - Amgen - Sanofi - Seattle Genetics - Genentech - MedImmune - Merck & Co - Millennium Pharmaceuticals - Biocon Limited - Ono Pharmaceutical - Sandoz - Celgene Corporation - Incyte Corporation - Merck KGaA - Immunomedics - Portola Pharmaceuticals - Pharmacyclics - Senesco Technologies - Simcere Pharmaceutical - Spectrum Pharmaceuticals - Abiogen Pharma. - Provenance Biopharmaceuticals - LFB Biotechnologies - Areta International - Molecular Templates - Aprogen - BioMedics Japan - Pharmapraxis For more information visit http://www.researchandmarkets.com/research/fvkt8j/bcell (full story)
MorphoSys and Merck Serono Enter Strategic Immuno-Oncology Collaboration
GlobeNewswire - Thu Jun 12, 12:36AM CDT
-- Co-development and license agreement that complements and further expands Merck Serono's immuno-oncology portfolio (full story)
Achillion Surges Two Days in a Row, HCV in Focus - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jun 11, 4:10PM CDT
Achillion Pharmaceuticals, Inc. (ACHN) announced that the FDA has removed the clinical hold on its hepatitis C virus (HCV) candidate, sovaprevir. (full story)
Why Wall Street Hates Inovio Pharmaceuticals
George Budwell, The Motley Fool - Motley Fool - Wed Jun 11, 4:01PM CDT
Because short-sellers take on substantially more risk than individuals long a stock, they tend to be some of the more sophisticated and informed investors in the marketplace. So when they decide to jump into a stock with both feet, it's probably a... (full story)
ASCO 2014: Competition Heats Up
Cheryl Swanson, The Motley Fool - Motley Fool - Wed Jun 11, 3:42PM CDT
Gains in cancer research are maddeningly hard to understand, and many new drug regimens are extremely toxic. That's what analysts from BMO Capital seized upon, when they issued a negative report on biopharma Bristol-Meyers Squibb . The report was... (full story)
Feed Your Brain Daily: Read, Study, Mingle
at Investor's Business Daily - Wed Jun 11, 1:12PM CDT
Great leaders have a relentless passion for growth, says Waldo Waldman, a decorated fighter pilot and author of "Never Fly Solo." Waldman, a graduate of the Air Force Academy who holds an MBA with a focus on organizational behavior, says chiefs who... (full story)
Dow Today: Merck (MRK) Higher
at The Street - Wed Jun 11, 1:00PM CDT
The Dow component leading the way higher looks to be Merck (NYSE: MRK ), which is sporting a 32-cent gain (+0.5%) bringing the stock to $58.80. (full story)
Today's Top Performers In Health Care
at The Street - Wed Jun 11, 12:03PM CDT
TheStreet highlights 3 stocks pushing the health care sector higher today. (full story)
A Disappointing Dow Isn't Holding Back Merck and ExxonMobil
Dan Caplinger, The Motley Fool - Motley Fool - Wed Jun 11, 11:30AM CDT
The Dow Jones Industrials on Wednesday finally lost some of its heat , falling 88 points as of 12:30 p.m. EDT. After such a strong rally, many traders have grown increasingly worried about the prospects for a sustained downdraft in the Dow; as the... (full story)
Overall Average: 80% Buy
Recent stock forum discussions about MRK http://investorshangout.com/search?q=MRK&...mp;yt0=Go!
As the Dow Declines, Why Are Pfizer and Merck Rising?
Dan Caplinger, The Motley Fool - Motley Fool - Thu Jun 12, 11:31AM CDT
The Dow Jones Industrials was down 50 points as of 12:30 p.m. EDT Thursday, extending the previous day's loss . With unrest in Iraq helping to boost energy prices , the prospects for consumers having to pay more at the pump and for businesses... (full story)
Watch for Shares of Merck (MRK) to Approach Support at $58.12
Comtex SmarTrend(R) - Thu Jun 12, 9:41AM CDT
Merck (NYSE:MRK) has opened bearishly below the pivot of $58.75 today and has reached the first level of support at $58.46. Investors may be interested in a cross of the next downside pivot targets of $58.12 and $57.49. (full story)
Will This Price Target Increase Help Merck (MRK) Stock Today?
at The Street - Thu Jun 12, 8:22AM CDT
Bank of America-Merrill Lynch raises its price target for Merck (MRK) to $65, saying the Indentix purchase should add to earnings. (full story)
Latin America Nutraceuticals Industry Outlook to 2017 - Mexico and Brazil to Lead Growth
M2 - Thu Jun 12, 8:19AM CDT
Research and Markets (http://www.researchandmarkets.com/research/9vxhxk/latin_america) has announced the addition of the "Latin America Nutraceuticals Industry Outlook to 2017 - Mexico and Brazil to Lead Growth" report to their offering. The industry research report on -Latin America Nutraceuticals Industry Outlook to 2017 - Mexico and Brazil to Lead Growth- gives a comprehensive analysis of the nutraceutical industry past, present and future outlook. The report discusses Mexico and Brazil markets with outlook to 2017. Statistics include functional food, functional beverages and dietary supplements market size and competitive analysis. Additionally the sub-segments of the industry, ongoing trends and developments, import and export scenario, government regulations and impact are provided in the research publication. Key Topics covered in the report - The market size of the Latin America, Mexico and Brazil nutraceuticals industry on the basis of revenues - Market segmentation of the Latin America Nutraceuticals industry on the basis of types of products and benefits derived - Market segmentation of the Latin America Dietary supplements market on the basis of geography and distribution channels - Market Share of major players in Latin America Dietary supplements market - Market segmentation of the Mexico and Brazil Nutraceuticals industry on the basis of types of products - Market segmentation of the Functional Food and Beverages on the basis of product form in Mexico and Brazil - Market size of the Functional Foods and Functional Beverages in Mexico and Brazil Key Topics Covered: 1. Latin America Nutraceuticals Industry Introduction 2. Latin America Nutraceuticals Industry Size, 2006-2012 3. Latin America Nutraceuticals Market Segmentation 4. Latin America Nutraceuticals Industry Future Outlook and Projections, 2013-2017 5. Mexico Nutraceuticals Industry Introduction 6. Brazil Nutraceuticals Industry Introduction 7. Appendix Companies Mentioned: - Boehringer Ingelheim GmbH - Amway - Bayer HealthCare LLC - Groupe Danone - Herbalife - Ind?stria de Alimentos Bomgosto - M Dias Branco SA Ind?stria e Com?r - Merck Sharp & Dohme Corp - Nestle SA - Omnilife Group - PepsiCo - Pfizer Nutrition For more information visit http://www.researchandmarkets.com/research/9v...in_america (full story)
2014 Report on the International Antibacterial Drugs (minoglycosides, B-Lactams, Tetracyclines, Sulfonamides, Quinolones/ Fluoroquinolones, Macrolides and Phenicols) Market - Forecast to 2019
PR Newswire Europe - Thu Jun 12, 7:15AM CDT
Research and Markets (http://www.researchandmarkets.com/research/l2jzql/antibacterial [http://www.researchandmarkets.com/research/l2jzql/antibacterial]) has announced the addition of the "Antibacterial Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019" [http://www.researchandmarkets.com/research/l2jzql/antibacterial] report to their offering. (full story)
Alnylam Announces United States Patent and Trademark Office (USPTO) Issues Patent Covering RNAi Therapeutics for the Treatment of Hepatitis B Virus (HBV) Infection
Business Wire - Thu Jun 12, 7:01AM CDT
Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), a leading RNAi therapeutics company, announced today that the United States Patent and Trademark Office (USPTO) has issued a new patent (U.S. patent no. 8,618,277, or "'277 patent"
in the company's McSwiggen patent estate. The McSwiggen patent estate broadly describes chemical modifications of RNAi therapeutics needed to achieve "drug-like" properties in siRNA, the molecules that mediate RNAi. Specifically, the '277 patent includes claims that the company believes are critical for the development of RNAi therapeutics for the treatment of hepatitis B virus (HBV) infection. This patent is held exclusively by Alnylam and is not licensed to any third parties. The McSwiggen patent estate comprises a core component of Alnylam's overall intellectual property (IP) estate for the advancement of RNAi therapeutics, and was recently obtained through the company's acquisition of Sirna Therapeutics from Merck. (full story) Prophylactic Human Papillomavirus Vaccines Market Forecast to 2022
M2 - Thu Jun 12, 5:40AM CDT
RnRMarketResearch.com adds "PharmaPoint: Prophylactic Human Papillomavirus Vaccines - Global Drug Forecast and Market Analysis to 2022" report to its research database. (full story)
Renal Cell Carcinoma - Pipeline Review, H1 2014
M2 - Thu Jun 12, 3:49AM CDT
Research and Markets (http://www.researchandmarkets.com/research/5lwrwg/renal_cell) has announced the addition of the "Renal Cell Carcinoma - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Renal Cell Carcinoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Renal Cell Carcinoma and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Renal Cell Carcinoma - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Renal Cell Carcinoma and enlists all their major and minor projects Companies Mentioned: - Bristol-Myers Squibb - Boehringer Ingelheim - Kyowa Hakko Kirin - Amgen - Eli Lilly and Company - GlaxoSmithKline - Seattle Genetics - Genentech - Agenus - Merck & Co - Celltrion - Astellas Pharma - ImmunoGen - Ono - Pfizer - Taiho - Onyx - Bayer - Advaxis - Hemispherx - Celldex Therapeutics, Inc. - Active Biotech AB - Lorus Therapeutics Inc. - Lpath, Inc. - Bionomics Limited - Flamel Technologies S.A. - Mologen AG - Threshold Pharmaceuticals, Inc. - Colby Pharmaceutical Company - Wilex AG For more information visit http://www.researchandmarkets.com/research/5lwrwg/renal_cell (full story)
Complicated Intra-Abdominal Infections - Pipeline Review, H1 2014
M2 - Thu Jun 12, 3:03AM CDT
Research and Markets (http://www.researchandmarkets.com/research/qlldl7/complicated) has announced the addition of the "Complicated Intra-Abdominal Infections - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Complicated Intra-Abdominal Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Complicated Intra-Abdominal Infections and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Complicated Intra-Abdominal Infections - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Complicated Intra-Abdominal Infections and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects Companies Mentioned: - AstraZeneca PLC - Merck & Co., Inc. - Melinta Therapeutics, Inc - Cubist Pharmaceuticals, Inc. - MerLion Pharmaceuticals Pte Ltd - Atox Bio Inc. - Tetraphase Pharmaceuticals Inc. - Biota Pharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/ql...omplicated (full story)
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline Review, H1 2014
M2 - Thu Jun 12, 2:52AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7cwmg2/coronary_artery) has announced the addition of the "Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Coronary Artery Disease (CAD) (Ischemic Heart Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Coronary Artery Disease (CAD) (Ischemic Heart Disease) and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Coronary Artery Disease (CAD) (Ischemic Heart Disease) Companies Mentioned: - Bristol-Myers Squibb Company - AstraZeneca - MedImmune - Isis Pharmaceuticals - Gilead Sciences - Daiichi Sankyo Company - Merck & Co - CardioVascular BioTherapeutics - Bayer AG - AnGes MG - Pluristem Therapeutics - AngioDesign - ViroMed - Miltenyi Biotec - Multi Gene Vascular Systems - Lonestar Heart - Biscayne Pharmaceuticals For more information visit http://www.researchandmarkets.com/research/7c...ary_artery (full story)
B-Cell Non-Hodgkin Lymphoma - Pipeline Review, H1 2014
M2 - Thu Jun 12, 2:39AM CDT
Research and Markets (http://www.researchandmarkets.com/research/fvkt8j/bcell) has announced the addition of the "B-Cell Non-Hodgkin Lymphoma - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for B-Cell Non-Hodgkin Lymphoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for B-Cell Non-Hodgkin Lymphoma and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of B-Cell Non-Hodgkin Lymphoma - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for B-Cell Non-Hodgkin Lymphoma and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects Companies Mentioned: - Bristol-Myers Squibb Company - Johnson & Johnson - Boehringer Ingelheim - Amgen - Sanofi - Seattle Genetics - Genentech - MedImmune - Merck & Co - Millennium Pharmaceuticals - Biocon Limited - Ono Pharmaceutical - Sandoz - Celgene Corporation - Incyte Corporation - Merck KGaA - Immunomedics - Portola Pharmaceuticals - Pharmacyclics - Senesco Technologies - Simcere Pharmaceutical - Spectrum Pharmaceuticals - Abiogen Pharma. - Provenance Biopharmaceuticals - LFB Biotechnologies - Areta International - Molecular Templates - Aprogen - BioMedics Japan - Pharmapraxis For more information visit http://www.researchandmarkets.com/research/fvkt8j/bcell (full story)
MorphoSys and Merck Serono Enter Strategic Immuno-Oncology Collaboration
GlobeNewswire - Thu Jun 12, 12:36AM CDT
-- Co-development and license agreement that complements and further expands Merck Serono's immuno-oncology portfolio (full story)
Achillion Surges Two Days in a Row, HCV in Focus - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jun 11, 4:10PM CDT
Achillion Pharmaceuticals, Inc. (ACHN) announced that the FDA has removed the clinical hold on its hepatitis C virus (HCV) candidate, sovaprevir. (full story)
Why Wall Street Hates Inovio Pharmaceuticals
George Budwell, The Motley Fool - Motley Fool - Wed Jun 11, 4:01PM CDT
Because short-sellers take on substantially more risk than individuals long a stock, they tend to be some of the more sophisticated and informed investors in the marketplace. So when they decide to jump into a stock with both feet, it's probably a... (full story)
ASCO 2014: Competition Heats Up
Cheryl Swanson, The Motley Fool - Motley Fool - Wed Jun 11, 3:42PM CDT
Gains in cancer research are maddeningly hard to understand, and many new drug regimens are extremely toxic. That's what analysts from BMO Capital seized upon, when they issued a negative report on biopharma Bristol-Meyers Squibb . The report was... (full story)
Feed Your Brain Daily: Read, Study, Mingle
at Investor's Business Daily - Wed Jun 11, 1:12PM CDT
Great leaders have a relentless passion for growth, says Waldo Waldman, a decorated fighter pilot and author of "Never Fly Solo." Waldman, a graduate of the Air Force Academy who holds an MBA with a focus on organizational behavior, says chiefs who... (full story)
Dow Today: Merck (MRK) Higher
at The Street - Wed Jun 11, 1:00PM CDT
The Dow component leading the way higher looks to be Merck (NYSE: MRK ), which is sporting a 32-cent gain (+0.5%) bringing the stock to $58.80. (full story)
Today's Top Performers In Health Care
at The Street - Wed Jun 11, 12:03PM CDT
TheStreet highlights 3 stocks pushing the health care sector higher today. (full story)
A Disappointing Dow Isn't Holding Back Merck and ExxonMobil
Dan Caplinger, The Motley Fool - Motley Fool - Wed Jun 11, 11:30AM CDT
The Dow Jones Industrials on Wednesday finally lost some of its heat , falling 88 points as of 12:30 p.m. EDT. After such a strong rally, many traders have grown increasingly worried about the prospects for a sustained downdraft in the Dow; as the... (full story)
